High-Dose-Rate Brachytherapy Boost in Prostate Cancer Improves QOL
SAN ANTONIO — Men with intermediate- and high-risk prostate cancer treated with external-beam pelvic radiotherapy (EBRT) had better quality of life (QOL) outcomes when the combined prostate brachytherapy boost had a high dose rate (HDR), according to research presented here. In a randomized phase III trial comparing health-related QOL outcomes after either low dose rate […]
Immunotherapy Combo in Advanced RCC Led to More Time Off Treatment
Nearly one-fifth of patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC) treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the CheckMate 214 trial were alive and treatment free beyond 3 years. Among the phase III trial participants, the treatment-free survival (TFS) rate at 42 months was 18% for those who were randomized to […]